GLP-1 injections recalled nationwide over sterility concerns

Live updates

1. 1h ago

   Nationwide GLP-1 Injections Recalled Over Sterility Risks

   Federal regulators have initiated a nationwide recall of specific compounded GLP-1 and NAD+ injectable medications due to a lack of assurance of sterility. Apothecary Pharma issued the recall for the affected products, which include tirzepatide weight-loss injections distributed across the United States. The Food and Drug Administration raised the risk level of the recall to the second-highest category, known as Class II. Patients using these specific compounded weight-loss treatments are urged to check product details to determine if their medication is safe, following warnings from health authorities regarding the company's manufacturing practices.

   Why it matters

   The safety action targets compounded versions of popular weight-loss and diabetes treatments amid heightened scrutiny over compounded medications. Compounded drugs are custom-mixed by pharmacies rather than mass-produced by major manufacturers like original patent holders, leaving them outside standard FDA drug approval pathways. The Food and Drug Administration previously issued warnings to Apothecary Pharma regarding its production practices before escalating the current recall to a Class II risk level.

   What is confirmed

   • Apothecary Pharma is recalling compounded GLP-1 and NAD+ injections nationwide over sterility concerns.
   • The Food and Drug Administration previously warned Apothecary Pharma about its production practices.
   • The recall involves compounded injectable tirzepatide distributed across the United States.
   • Federal regulators classified the recall risk at the second-highest level.

   Still unconfirmed

   • Apothecary Pharma is specifically recalling 22 vials of injectable tirzepatide according to certain reports.
   • The Food and Drug Administration stated that 23 vials of compounded injectable drugs are involved in the recall.

   What to watch next

   • Further regulatory actions or inspection results regarding Apothecary Pharma facilities
   • Additional product lot numbers added to the nationwide recall list
   Sources used for this update (12)

   1. nypost.com — New York Post – Breaking News, Top Headlines, Photos & Videos
   2. USA Today — GLP-1 injections recalled nationwide. See affected products
   3. Fox Business — GLP-1 injections recalled nationwide over sterility concerns
   4. MassLive — GLP-1 recall: Mounjaro, Zepbound ingredient risk raised to second-highest level
   5. qz.com — Apothecary Pharma recalls tirzepatide injections over sterility
   6. Los Angeles Times — Some GLP-1 injections recalled due to ‘lack of assurance of sterility’
   7. New York Post — GLP-1 injections recalled nationwide over concerning reason
   8. cashwalklabs.io — GLP-1 injections recalled nationwide. See affected products | Global Cashwalk
   9. www.foxbusiness.com — GLP-1 injections recalled nationwide over sterility concerns, FDA says | Fox Business
   10. www.unilad.com — GLP-1 medication Tirzepatide recalled over safety and sterility concerns
   11. www.livenowfox.com — FDA recalls GLP-1 drug, other injectable medication over sterility concerns | LiveNOW from FOX
   12. nypost.com — GLP-1 injections recalled nationwide over concerning reason
   confidence 100%